<SEC-DOCUMENT>0001628280-22-006570.txt : 20220317
<SEC-HEADER>0001628280-22-006570.hdr.sgml : 20220317
<ACCEPTANCE-DATETIME>20220317170502
ACCESSION NUMBER:		0001628280-22-006570
CONFORMED SUBMISSION TYPE:	8-K/A
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20220317
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220317
DATE AS OF CHANGE:		20220317

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		22749728

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K/A
<SEQUENCE>1
<FILENAME>cpix-20220317.htm
<DESCRIPTION>8-K/A
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:e2c3d170-12b7-41fc-8d34-d657306939bd,g:ac02975c-0cd6-434a-8ef5-7392c7d87dc7,d:0a55aaef8f754e0d91976c6070cb18ff--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20220317</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xMC9mcmFnOjA1ODA0NWI0MmIyYzQxNjQ4MTQ1NzQxMTliMDhiN2JhL3RhYmxlOjFkYjU4NTFkMzk3NzRkMDRiZWJiYjQyZmY2MzFkZmYzL3RhYmxlcmFuZ2U6MWRiNTg1MWQzOTc3NGQwNGJlYmJiNDJmZjYzMWRmZjNfMi0xLTEtMS0xMjg0Mg_97956d8a-1a0c-42ad-851f-5a2a7d989fae">0001087294</ix:nonNumeric><ix:nonNumeric contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xMC9mcmFnOjA1ODA0NWI0MmIyYzQxNjQ4MTQ1NzQxMTliMDhiN2JhL3RhYmxlOjFkYjU4NTFkMzk3NzRkMDRiZWJiYjQyZmY2MzFkZmYzL3RhYmxlcmFuZ2U6MWRiNTg1MWQzOTc3NGQwNGJlYmJiNDJmZjYzMWRmZjNfMy0xLTEtMS0xMjg0Mg_8b9ddb8f-16e6-4fb9-8f27-2f5c900d4812">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cpix-20220317.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-17</xbrli:startDate><xbrli:endDate>2022-03-17</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0a55aaef8f754e0d91976c6070cb18ff_1"></div><div style="min-height:29.25pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:174%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:144%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:144%">FORM <ix:nonNumeric contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNzA3_b37a371f-20d5-4db2-9aea-3d85ba8ad6ea">8-K/A</ix:nonNumeric> </span></div><div style="margin-top:11pt;padding-left:108pt;padding-right:108pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNzY_a869308b-6b60-4a72-948e-e633f3b1d50d">March 17, 2022</ix:nonNumeric> (March 17, 2022)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Report (date of earliest event reported)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNzAy_9e5b82d6-eb94-4f5b-ab08-7f1dbf7c25cf">CUMBERLAND PHARMACEUTICALS INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGFibGU6MDU4NjMzMzdiMzJkNDhmMzkyNzc0NDM5YmIxZTRmNmMvdGFibGVyYW5nZTowNTg2MzMzN2IzMmQ0OGYzOTI3NzQ0MzliYjFlNGY2Y18wLTAtMS0xLTEyODQy_1a0d9c83-e2dc-466d-9fe3-5063dac300d7">Tennessee</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGFibGU6MDU4NjMzMzdiMzJkNDhmMzkyNzc0NDM5YmIxZTRmNmMvdGFibGVyYW5nZTowNTg2MzMzN2IzMmQ0OGYzOTI3NzQ0MzliYjFlNGY2Y18wLTEtMS0xLTEyODQy_879b4da5-86f7-44c5-af61-809db6193c1b">001-33637</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGFibGU6MDU4NjMzMzdiMzJkNDhmMzkyNzc0NDM5YmIxZTRmNmMvdGFibGVyYW5nZTowNTg2MzMzN2IzMmQ0OGYzOTI3NzQ0MzliYjFlNGY2Y18wLTMtMS0xLTEyODQy_8e624602-5b23-43e4-b643-c5d15008287c">62-1765329</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNzAz_65b23342-238a-4665-ad0e-dfcbb2631db4">2525 West End Avenue, Suite 950</ix:nonNumeric> <ix:nonNumeric contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNzA0_3a831763-e4c4-4c5d-9bb4-fe0eeae6c66a">Nashville</ix:nonNumeric>, <ix:nonNumeric contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNjk3_803c9990-8157-424b-93b4-cd5ed80a8f4e">Tennessee</ix:nonNumeric> <ix:nonNumeric contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNjk4_4bdc2e6a-0366-496c-92bd-d14945ea21a2">37203</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">(Address of Principal Executive Offices)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">(<ix:nonNumeric contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNjk5_d3d533d8-a9eb-43a5-a2c5-d550d90e8e7d">615</ix:nonNumeric>) <ix:nonNumeric contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNzA4_632761c7-a9d8-47a7-b48a-b47b83966be3">255-0068</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Registrant's telephone number, including area code</span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNzAw_37c409fd-1794-4538-9937-bea49e185d98">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNzA5_a5ab4699-45eb-43fc-b0de-1dbfe62be8c4">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNzAx_53bdb7de-3713-4642-afe3-b098d436b0c9">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNzA1_d2e54366-e415-410a-8036-5f65eb86b793">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:33.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGFibGU6NDU2MGFlYWRjMDVhNGFmOGExNWFhNTg0MTE4NmRiNDAvdGFibGVyYW5nZTo0NTYwYWVhZGMwNWE0YWY4YTE1YWE1ODQxMTg2ZGI0MF8xLTAtMS0xLTEyODQy_4c5644a3-db5b-487b-8752-5df79bf6cf14">Common Stock, no par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGFibGU6NDU2MGFlYWRjMDVhNGFmOGExNWFhNTg0MTE4NmRiNDAvdGFibGVyYW5nZTo0NTYwYWVhZGMwNWE0YWY4YTE1YWE1ODQxMTg2ZGI0MF8xLTEtMS0xLTEyODQy_a192c411-38e6-46f9-b591-e9ca06dabb9c">CPIX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGFibGU6NDU2MGFlYWRjMDVhNGFmOGExNWFhNTg0MTE4NmRiNDAvdGFibGVyYW5nZTo0NTYwYWVhZGMwNWE0YWY4YTE1YWE1ODQxMTg2ZGI0MF8xLTItMS0xLTEyODQy_60d397c0-d771-47ed-918f-b3ed0563c1ff">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNzA2_0069f2a8-b71f-4334-adb9-afd7554dc29f">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNjk1_0069f2a8-b71f-4334-adb9-afd7554dc29f">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:24.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0a55aaef8f754e0d91976c6070cb18ff_4"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXPLANATORY NOTE</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2021, Cumberland Pharmaceuticals, Inc. (the Company or Cumberland) signed and entered into a definitive agreement (the "Agreement") to acquire the rights to Sancuso&#174; (the "Product") from Kyowa Kirin, Inc. (KKI). On January 3, 2022, Cumberland</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquired from KKI the assets, related to the manufacture, marketing and sale of KKI&#8217;s proprietary medicine, Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the "Acquisition") described in the previously announced Asset Purchase Agreement dated December 31, 2021. Pursuant to Item 9.01(a)(4) and Item 9.01(b) of Form 8-K, this Amendment No. 1 to Form 8-K is being filed to amend and supplement the Company&#8217;s Current Report on Form 8-K, filed on January 6, 2022, to include the required historical audited and unaudited financial statements of Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the related pro forma financial information not later than 71 calendar days after January 6, 2022, the date that the initial Current Report on Form 8-K was required to have been filed to report the completion of the Asset Purchase of Sancuso. Except as provided herein, this Amendment No. 1 effects no other changes to the original Form 8-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Amendment, including the Exhibits attached hereto, contains &#8220;forward-looking statements&#8221; and information within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, which are subject to the &#8220;safe harbor&#8221; created by those sections. These forward-looking statements include, but are not limited to, statements concerning our future financial position, future revenues, and projected costs, savings and synergies. The words &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;future&#8221;, &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;pro forma&#8221;, &#8220;projects,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that could cause our actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation: market conditions; competition; an inability of manufacturers or partners to supply the Company&#8217;s products on a timely basis,  failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers; maintaining an effective sales and marketing infrastructure; product sales; management of our growth and integration of our acquisitions; our ability to successfully integrate the Product into the Company&#8217;s business, as well as other risks discussed in the &#8220;Risk Factors&#8221; section of the Company's most recent Annual Report on Form 10-K, and other filings with the SEC. Readers of this Amendment No. 1 to Form 8-K are cautioned not to place undue reliance on forward-looking statements contained herein, which speak only as of the date stated, or if no date is stated, as of the date of this Current Report. The Company undertakes no obligation to publicly update or revise the forward-looking statements contained herein to reflect changes events or circumstances after the date of this release, unless required by law. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We describe assumptions, which management believes are reasonable, underlying the pro forma adjustments in the Unaudited Pro Forma Condensed Combined Financial Statements (Combined Cumberland and Sancuso Product Line of Kyowa Kirin, Inc.) and the accompanying notes.  These assumptions should also be read in conjunction with the unaudited pro forma financial statements.  It is important to note that the assumptions do not reflect the expected future significant cost savings, benefits or synergies from the Acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements and Exhibits</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Financial Statements of Business Acquired.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following audited special purpose financial statements of the Sancuso product line of KKI are filed as Exhibit 99.1 attached hereto and are incorporated herein by reference: (i) Audited Special Purpose Statement of Assets Acquired and Liabilities Assumed as of December 31, 2020; (ii) Audited Special Purpose Statement of Revenues and Direct Expenses for the year ended December 31, 2020; and (iii) the notes related thereto, including the Independent Auditor&#8217;s Report contained therein. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited special purpose financial statements of the Sancuso product line of KKI are filed as Exhibit 99.2 attached hereto and are incorporated herein by reference: (i) Unaudited Special Purpose Statement of Assets Acquired and Liabilities Assumed as of September 30, 2021; (ii) Unaudited Special Purpose Statement of Assets and Liabilities assumed as of September 30, 2021; and (iii) the notes related thereto.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Pro Forma Financial Information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma condensed combined financial information (of Cumberland and the Sancuso product line) and related notes is filed as Exhibit 99.3 and incorporated in its entirety herein by reference: (i) Unaudited Pro Forma Condensed Combined Balance Sheet as of September 30, 2021; and (ii) Unaudited Pro Forma Condensed Combined Statement of Income for the year ended December 31, 2020, and for the nine months ended September 30, 2021; and (iii) the notes related thereto.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits. The following exhibits are filed herewith:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.140%"><tr><td style="width:1.0%"></td><td style="width:17.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.793%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1087294/000162828022000440/finalforexecutionkkuscipde.htm">2.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1087294/000162828022000440/finalforexecutionkkuscipde.htm">Asset Purchase Agreement, dated December 31, 2021, by and among Cumberland Pharmaceuticals Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1087294/000162828022000440/finalforexecutionkkuscipde.htm">, and Kyowa Kirin, Inc.* </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit231consentofindepen.htm">23.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit231consentofindepen.htm">Consent of Independent Auditors</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991auditedspecialpu.htm">99.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991auditedspecialpu.htm">Audited special purpose financial statements of Sancuso Product Line of Kyowa Kirin Inc. as of and for the fiscal year ended December 31, 2020 </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit992unauditedspec.htm">99.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit992unauditedspec.htm">Unaudited special purpose financial statements of Sancuso Product Line of Kyowa Kirin, Inc. as of  and for the nine-month period ended September 30, 2021</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit993unauditedproform.htm">99.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit993unauditedproform.htm">Unaudited pro forma condensed combined financial information (of Cumberland and the Sancuso Product Line) as of and for the nine-month period ended on September 30, 2021 and the year period ended December 31, 2020</a></span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Previously filed with the Current Report on Form 8-K, filed on January 6, 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0a55aaef8f754e0d91976c6070cb18ff_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:11.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:16.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumberland Pharmaceuticals Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: March 17, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>exhibit231consentofindepen.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i120563c089324dddaabe815a1e1894cd_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Exhibit 23.1</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Consent of Independent Auditors</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-251308) and Form S-8 (No. 333-164376) of Cumberland Pharmaceuticals Inc. of our report dated March 17, 2022, relating to the special purpose financial statements of the SANCUSO Product Line of Kyowa Kirin, Inc., which appears in this Current Report on Form 8-K&#47;A of Cumberland Pharmaceuticals Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">&#47;s&#47; Bodwell Vasek Wells DeSimone LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Dallas, Texas</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">March 17, 2022</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>exhibit991auditedspecialpu.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i32996194b66441dd9d29bcc60abbdc37_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 99.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">REPORT OF INDEPENDENT AUDITORS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To the Management of</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kyowa Kirin, Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have audited the accompanying special purpose financial statements of the SANCUSO Product Line (&#8220;SANCUSO&#8221;) of Kyowa Kirin, Inc. (the &#8220;Company&#8221;), which comprise the special purpose statement of assets acquired and liabilities assumed as of December 31, 2020, and the related special purpose statement of revenue and direct expenses for the year then ended, and the related notes to the special purpose financial statements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Management&#8217;s Responsibility for the Special Purpose Financial Statements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management is responsible for the preparation and fair presentation of these special purpose financial statements in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;)&#59; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of the special purpose financial statements that are free from material misstatement, whether due to fraud or error.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Auditor&#8217;s Responsibility</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our responsibility is to express an opinion on these special purpose financial statements based on our audit.  We conducted our audit in accordance with auditing standards generally accepted in the United States of America.  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the special purpose financial statements are free from material misstatement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements.  The procedures selected depend on the auditor&#8217;s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.  In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity&#8217;s internal control.  Accordingly, we express no such opinion.  An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Opinion</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In our opinion, the special purpose financial statements referred to above present fairly, in all material respects, the assets acquired and liabilities assumed of the SANCUSO Product Line of Kyowa Kirin, Inc. as of December 31, 2020, and the results of its revenue and direct expenses for the year then ended in conformity with GAAP.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Emphasis of Matter&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The accompanying special purpose financial statements and related notes were prepared in connection with the Company&#8217;s transaction related to the SANCUSO Product Line, as described in Note A, and were prepared in accordance with an SEC waiver received by the buyer, for the purposes of the buyer complying with Rule 3-05 of the Securities and Exchange Commission&#8217;s Regulation S-X. These special purpose financial statements are not intended to be a complete presentation of the financial position or results of operations of the SANCUSO Product Line of Kyowa Kirin, Inc. Our opinion is not modified with respect to this matter.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#47;s&#47; Bodwell Vasek Wells DeSimone LLP</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dallas, Texas</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 17, 2022</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SANCUSO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> PRODUCT LINE OF KYOWA KIRIN, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Special Purpose Statement of Assets Acquired and Liabilities Assumed</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:7pt;text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.553%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets acquired</font></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="4" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620,426&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,486,992</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:22.85pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</font></div></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107,418</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,915,834</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</font></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="4" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,023,252&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">See accompanying notes to special purpose financial statements.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">SANCUSO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%"> PRODUCT LINE OF KYOWA KIRIN, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Special Purpose Statement of Revenue and Direct Expenses</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:7pt;text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.912%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-left:0.35pt;padding-right:0.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended</font></div><div style="margin-bottom:2pt;padding-left:0.35pt;padding-right:0.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="8" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,171,293</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct expenses&#58;</font></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</font></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160,987&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</font></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,636,827&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126,548&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,176&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</font></td><td colspan="5" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,728,958&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total direct expenses</font></td><td colspan="5" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,981,496&#160;</font></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess of revenue over direct expenses</font></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="4" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189,797&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;See accompanying notes to special purpose financial statements.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i32996194b66441dd9d29bcc60abbdc37_4"></div><hr style="page-break-after:always"><div style="min-height:151.2pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SANCUSO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> PRODUCT LINE OF KYOWA KIRIN, INC.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOTES TO SPECIAL PURPOSE FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2020</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A.&#160;&#160;&#160;&#160;Nature of Business</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Kyowa Kirin, Inc. (&#8220;Kyowa Kirin&#8221;, the &#8220;Company&#8221;, or &#8220;we&#8221; and other similar pronouns) is a global specialty pharmaceutical company that strives to create and deliver novel medicines with life-changing value. SANCUSO&#174; (the &#8220;SANCUSO Product&#8221;) is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in SANCUSO, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient&#8217;s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (CINV).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">On December 31, 2021, Cumberland Pharmaceuticals Inc. (&#8220;Cumberland&#8221;) signed and entered into a definitive agreement (the &#8220;Agreement&#8221;) to acquire the U.S. rights to SANCUSO from Kyowa Kirin. Under the terms of the Agreement, Cumberland acquired the U.S. rights to SANCUSO and assumed full commercial responsibility for the product &#8211; including its marketing, promotion, distribution, manufacturing and medical support activities. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The financial terms of the acquisition included a $13.5 million payment to Kyowa Kirin upon closing, up to $3.5 million in milestones and tiered royalties ranging from 10% to 5% on U.S. net product sales for ten years. Kyowa Kirin will retain international rights, continuing to deliver the product to address oncology patients&#8217; needs throughout the rest of the world.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company retained financial responsibility for any liabilities relating to products sold prior to transaction closing, and Cumberland assumed financial responsibility for any liabilities relating to products sold on or after transaction closing.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Basis of Accounting</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The accompanying special purpose financial statements (the &#8220;Financial Statements&#8221;) were prepared to present the net assets sold pursuant to the Agreement and the revenue and direct expenses related to the net assets sold. The Financial Statements will be included in an 8-K filing of Cumberland as required by Rule 3-05, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Significant Acquisition Carveout Financial Statement Reporting Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, of the US Securities and Exchange Commission&#8217;s (&#8220;SEC&#8221;) Regulation S-X. The basis of accounting describes how these Financial Statements have been prepared.</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:151.2pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SANCUSO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> PRODUCT LINE OF KYOWA KIRIN, INC.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOTES TO SPECIAL PURPOSE FINANCIAL STATEMENTS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">(continued)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.   Summary of Significant Accounting Policies</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Basis of Accounting</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The accompanying special purpose statements of assets acquired and liabilities assumed as of December 31, 2020, and of revenue and direct expenses for the year then ended of the Company&#8217;s SANCUSO Product represent an incomplete presentation of the Company&#8217;s assets, liabilities, revenues and expenses and are therefore not intended to represent the financial condition or results of operations of the Company. These Financial Statements are based upon the Agreement and relief from SEC Rule 3-05 obtained by Cumberland from the SEC. The statement of assets acquired and liabilities assumed only presents the assets acquired and liabilities assumed in accordance with the Agreement, and the statement of revenue and direct expenses presents only those revenues and estimated expenses related directly to the SANCUSO Product to be acquired. The statement of revenue and direct expenses excludes costs not directly involved with the revenue producing activity, such as overhead, interest and taxes. The funding and management of the Company&#8217;s operations (including the SANCUSO Product) are performed on a consolidated basis&#59; accordingly, costs of funding the operations, including debt and related interest expense were not allocated to the SANCUSO Product. The Company also maintains its tax functions on a consolidated basis&#59; accordingly, tax expense was not allocated to the SANCUSO Product. The Financial Statements were derived from the historical accounting records of the Company and were prepared in accordance with the basis of accounting described in these notes, which is in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As the SANCUSO Product has historically been managed as a part of the Company and has not been accounted for on a stand-alone basis, it is not practicable to prepare complete financial statements, including these accompanying notes, related to the SANCUSO Product. As a result, these Financial Statements may not be indicative of the complete financial condition or results of operations of the SANCUSO Product on a stand-alone basis. In addition, certain costs and expenses presented in these special purpose financial statements have been allocated by the Company based on a specific identification basis or, when specific identification was not practicable, a proportional cost allocation method (primarily headcount), depending on the nature of the services rendered. The allocations and estimates used to derive the amounts in the statement of revenue and direct expenses are based in part on judgments and assumptions that the Company believes are reasonable, but may not necessarily be indicative of the costs that would have been incurred if the SANCUSO Product had been operated on a stand-alone basis for the period presented.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Use of Estimates</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The preparation of these Financial Statements requires management to make certain estimates and assumptions that affect the reported amounts of assets, revenue and expenses. Such estimates and assumptions are made in conformity with GAAP. Actual outcomes and results could differ from these estimates and assumptions. These Financial Statements include allocations and estimates that are not necessarily indicative either of the costs and assets that would have resulted if the SANCUSO Product had been operated as a separate business, or of the future results of the SANCUSO Product. The Financial Statements presented are not indicative of the financial condition or results of operations of the SANCUSO Product going forward because of the omission of various operating expenses. The Company based its estimates on historical experience and other relevant assumptions that the Company believes to be reasonable under the circumstances.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i32996194b66441dd9d29bcc60abbdc37_7"></div><hr style="page-break-after:always"><div style="min-height:126pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SANCUSO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> PRODUCT LINE OF KYOWA KIRIN, INC.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOTES TO SPECIAL PURPOSE FINANCIAL STATEMENTS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">(continued)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies &#8211; continued </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Inventories</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Inventories consist of raw materials and finished goods related to the production of the SANCUSO Product. Raw materials include the SANCUSO Product&#8217;s active pharmaceutical ingredient (&#8220;API&#8221;) and other raw materials. Finished goods include third&#8209;party manufacturing costs and labor and indirect costs we incur in the production process. We determine the cost of inventory using the average&#8209;cost method.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">We assess our inventory levels each reporting period and write&#8209;down inventory that is expected to be at risk for expiration, that has a cost basis in excess of its expected net realizable value and inventory quantities in excess of expected requirements. In evaluating the sufficiency of our inventory reserves or liabilities for firm purchase commitments, we also take into consideration our firm purchase commitments for future inventory production. If we were to decide to cancel our manufacturing commitment, such cancellation would trigger the payment of a cancellation fee. If we project to have excess inventories and that it would be more cost-efficient to pay the cancellation fee, we may accrue the cancellation fee as a liability. Our assessment of excess inventories, including future firm purchase commitments, requires management to utilize judgement in formulating estimates and assumptions that we believe to be reasonable under the circumstances. Actual results may differ from those estimates and assumptions. As of December 31, 2020, no accrued liability related to excess inventory purchase commitments was recorded.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">When we recognize a loss on such inventory or firm purchase commitments, it establishes a new, lower cost basis for that inventory, and subsequent changes in facts and circumstances will not result in the restoration or increase in that newly established cost basis. If inventory with a lower cost basis is subsequently sold, it will result in higher gross margin for those sales. In 2020, the Company recognized no charges arising from excess inventory.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Intangible Assets</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">On July 1, 2019, the Company entered into a confirmatory assignment of patents and trademarks agreement that included all intangible product rights for the SANCUSO Product for $31.5 million.  The value of the intangible product rights is being amortized on a straight-line basis over the remaining lives of such intangible product rights, which end on December 31, 2024.  The Company evaluates its long-lived assets including definite lived and indefinite lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Recoverability of these assets is measured by comparison of their carrying amounts to future undiscounted cash flows that the assets are expected to generate.  If long-lived assets are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair market value and is recorded in the period the determination was made.  Based upon management&#8217;s assessment, there was no impairment of long-lived assets at December 31, 2020.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">At December 31, 2020, the Company&#8217;s intangible assets future amortization expense will be $5.7 million each year for 2021, 2022, 2023 and 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:126pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SANCUSO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> PRODUCT LINE OF KYOWA KIRIN, INC.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOTES TO SPECIAL PURPOSE FINANCIAL STATEMENTS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">(continued)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies &#8211; continued </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Revenue Recognition</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company recognizes revenue when control of the promised goods is transferred to the customer in an amount that reflects the consideration the Company expects to receive in exchange for those goods.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Product Sales</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company recognizes revenue upon shipment to the customer as that is when the customer obtains control of the promised goods.  The Company typically extends credit terms to customers based on their creditworthiness and generally do not receive advance payments.  As such, the Company records accounts receivable at the time of shipment, when the right to the consideration becomes unconditional.  Accounts receivable from customers are typically due within 30 &#8211; 60 days of invoicing.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Performance Obligations</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Product sales do not include multiple performance obligations.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Judgments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company considers several factors in determining that control transfers to the customer upon delivery of goods.  These factors include that legal title transfers to the customer, the Company has a present right to payment, and the customer has assumed the risks and rewards of ownership at the time of shipment.  During the year ended December 31, 2020, product returns were not significant.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Shipping and Handling Costs</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Costs for shipping and handling activities are recorded as cost of sales and are expensed as incurred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research and Development Expenses</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development expenses are recorded in the period that services are rendered or goods are received. Research and development expenses consist of fees paid to related third parties that conduct certain research and development activities on our behalf. </font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">C.  Prepaid Expenses</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prepaid expenses consisted of the following at December 31, 2020&#58;</font></div><div><font><br></font></div><div style="padding-left:65.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.275%"><tr><td style="width:1.0%"></td><td style="width:72.070%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prescription drug user fee amendments (PDUFA)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.1pt;padding-right:6.7pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$      252,324</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Production facility fee advance</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.1pt;padding-right:6.7pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,234,668</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:3.1pt;padding-right:6.7pt;text-align:right"><font><br></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:3.1pt;padding-right:6.7pt;text-align:right"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:3.1pt;padding-right:6.7pt;text-align:right"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.1pt;padding-right:6.7pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$   1,486,992</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:3.1pt;padding-right:6.7pt;text-align:right"><font><br></font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:126pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SANCUSO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> PRODUCT LINE OF KYOWA KIRIN, INC.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOTES TO SPECIAL PURPOSE FINANCIAL STATEMENTS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">(continued)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">D.&#160;&#160;&#160;&#160;Inventories</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Inventories consisted of the following at December 31, 2020&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:65.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.275%"><tr><td style="width:1.0%"></td><td style="width:72.070%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Raw materials</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.1pt;padding-right:6.7pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$      446,614</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Finished goods</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.1pt;padding-right:6.7pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">173,812</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:3.1pt;padding-right:6.7pt;text-align:right"><font><br></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:3.1pt;padding-right:6.7pt;text-align:right"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:3.1pt;padding-right:6.7pt;text-align:right"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.1pt;padding-right:6.7pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$      620,426</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:3.1pt;padding-right:6.7pt;text-align:right"><font><br></font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>4
<FILENAME>exhibit992unauditedspec.htm
<DESCRIPTION>EX-99.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if010046afb114c55ab8d9244de3389c2_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 99.2</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SANCUSO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> PRODUCT LINE OF KYOWA KIRIN, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Special Purpose Statement of Assets Acquired and Liabilities Assumed</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">(Unaudited)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:7pt;text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.631%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021 2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets acquired</font></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="4" style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223,776&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</font></td><td colspan="5" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,413&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:22.85pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</font></div></td><td colspan="5" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,593,189&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="5" style="border-bottom:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,619,115&#160;</font></td><td style="border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</font></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="4" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,212,304&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">See accompanying notes to special purpose financial statements.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">SANCUSO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%"> PRODUCT LINE OF KYOWA KIRIN, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Special Purpose Statement of Revenue and Direct Expenses</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Unaudited</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:7pt;text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.631%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-left:0.35pt;padding-right:0.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</font></div><div style="margin-bottom:2pt;padding-left:0.35pt;padding-right:0.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="5" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,619,070</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct expenses&#58;</font></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</font></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,455,129</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,907,522</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,324</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</font></td><td colspan="6" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,296,719</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total direct expenses</font></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,911,694</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess of revenue over direct expenses</font></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="4" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,707,376&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;See accompanying notes to special purpose financial statements.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="if010046afb114c55ab8d9244de3389c2_4"></div><hr style="page-break-after:always"><div style="min-height:151.2pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SANCUSO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> PRODUCT LINE OF KYOWA KIRIN, INC.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOTES TO SPECIAL PURPOSE FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30, 2021</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A.&#160;&#160;&#160;&#160;Nature of Business</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Kyowa Kirin, Inc. (&#8220;Kyowa Kirin&#8221;, the &#8220;Company&#8221;, or &#8220;we&#8221; and other similar pronouns) is a global specialty pharmaceutical company that strives to create and deliver novel medicines with life-changing value. SANCUSO&#174; (the &#8220;SANCUSO Product&#8221;) is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in SANCUSO, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient&#8217;s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (CINV).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">On December 31, 2021, Cumberland Pharmaceuticals Inc. (&#8220;Cumberland&#8221;) signed and entered into a definitive agreement (the &#8220;Agreement&#8221;) to acquire the U.S. rights to SANCUSO from Kyowa Kirin. Under the terms of the Agreement, Cumberland acquired the U.S. rights to SANCUSO and assumed full commercial responsibility for the product &#8211; including its marketing, promotion, distribution, manufacturing and medical support activities. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The financial terms of the acquisition included a $13.5 million payment to Kyowa Kirin upon closing, up to $3.5 million in milestones and tiered royalties ranging from 10% to 5% on U.S. net product sales for ten years. Kyowa Kirin will retain international rights, continuing to deliver the product to address oncology patients&#8217; needs throughout the rest of the world.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company retained financial responsibility for any liabilities relating to products sold prior to transaction closing, and Cumberland assumed financial responsibility for any liabilities relating to products sold on or after transaction closing.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Basis of Accounting</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The accompanying special purpose financial statements (the &#8220;Financial Statements&#8221;) were prepared to present the net assets sold pursuant to the Agreement and the revenue and direct expenses related to the net assets sold. The Financial Statements will be included in an 8-K filing of Cumberland as required by Rule 3-05, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Significant Acquisition Carveout Financial Statement Reporting Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, of the US Securities and Exchange Commission&#8217;s (&#8220;SEC&#8221;) Regulation S-X. The basis of accounting describes how these Financial Statements have been prepared.</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:151.2pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SANCUSO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> PRODUCT LINE OF KYOWA KIRIN, INC.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOTES TO SPECIAL PURPOSE FINANCIAL STATEMENTS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">(continued)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.   Summary of Significant Accounting Policies</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Basis of Accounting</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The accompanying special purpose statements of assets acquired and liabilities assumed as of September 30, 2021, and of revenue and direct expenses for the nine months then ended of the Company&#8217;s SANCUSO Product represent an incomplete presentation of the Company&#8217;s assets, liabilities, revenues and expenses and are therefore not intended to represent the financial condition or results of operations of the Company. These Financial Statements are based upon the Agreement and relief from SEC Rule 3-05 obtained by Cumberland from the SEC. The statement of assets acquired and liabilities assumed only presents the assets acquired and liabilities assumed in accordance with the Agreement, and the statement of revenue and direct expenses presents only those revenues and estimated expenses related directly to the SANCUSO Product to be acquired. The statement of revenue and direct expenses excludes costs not directly involved with the revenue producing activity, such as overhead, interest and taxes. The funding and management of the Company&#8217;s operations (including the SANCUSO Product) are performed on a consolidated basis&#59; accordingly, costs of funding the operations, including debt and related interest expense were not allocated to the SANCUSO Product. The Company also maintains its tax functions on a consolidated basis&#59; accordingly, tax expense was not allocated to the SANCUSO Product. The Financial Statements were derived from the historical accounting records of the Company and were prepared in accordance with the basis of accounting described in these notes, which is in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As the SANCUSO Product has historically been managed as a part of the Company and has not been accounted for on a stand-alone basis, it is not practicable to prepare complete financial statements, including these accompanying notes, related to the SANCUSO Product. As a result, these Financial Statements may not be indicative of the complete financial condition or results of operations of the SANCUSO Product on a stand-alone basis. In addition, certain costs and expenses presented in these special purpose financial statements have been allocated by the Company based on a specific identification basis or, when specific identification was not practicable, a proportional cost allocation method (primarily headcount), depending on the nature of the services rendered. The allocations and estimates used to derive the amounts in the statement of revenue and direct expenses are based in part on judgments and assumptions that the Company believes are reasonable, but may not necessarily be indicative of the costs that would have been incurred if the SANCUSO Product had been operated on a stand-alone basis for the period presented.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Use of Estimates</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The preparation of these Financial Statements requires management to make certain estimates and assumptions that affect the reported amounts of assets, revenue and expenses. Such estimates and assumptions are made in conformity with GAAP. Actual outcomes and results could differ from these estimates and assumptions. These Financial Statements include allocations and estimates that are not necessarily indicative either of the costs and assets that would have resulted if the SANCUSO Product had been operated as a separate business, or of the future results of the SANCUSO Product. The Financial Statements presented are not indicative of the financial condition or results of operations of the SANCUSO Product going forward because of the omission of various operating expenses. The Company based its estimates on historical experience and other relevant assumptions that the Company believes to be reasonable under the circumstances.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="if010046afb114c55ab8d9244de3389c2_7"></div><hr style="page-break-after:always"><div style="min-height:126pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SANCUSO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> PRODUCT LINE OF KYOWA KIRIN, INC.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOTES TO SPECIAL PURPOSE FINANCIAL STATEMENTS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">(continued)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies &#8211; continued </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Inventories</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Inventories consist of raw materials and finished goods related to the production of the SANCUSO Product. Raw materials include the SANCUSO Product&#8217;s active pharmaceutical ingredient (&#8220;API&#8221;) and other raw materials. Finished goods include third&#8209;party manufacturing costs and labor and indirect costs we incur in the production process. We determine the cost of inventory using the average&#8209;cost method.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">We assess our inventory levels each reporting period and write&#8209;down inventory that is expected to be at risk for expiration, that has a cost basis in excess of its expected net realizable value and inventory quantities in excess of expected requirements. In evaluating the sufficiency of our inventory reserves or liabilities for firm purchase commitments, we also take into consideration our firm purchase commitments for future inventory production. If we were to decide to cancel our manufacturing commitment, such cancellation would trigger the payment of a cancellation fee. If we project to have excess inventories and that it would be more cost-efficient to pay the cancellation fee, we may accrue the cancellation fee as a liability. Our assessment of excess inventories, including future firm purchase commitments, requires management to utilize judgement in formulating estimates and assumptions that we believe to be reasonable under the circumstances. Actual results may differ from those estimates and assumptions. As of December 31, 2020, no accrued liability related to excess inventory purchase commitments was recorded.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">When we recognize a loss on such inventory or firm purchase commitments, it establishes a new, lower cost basis for that inventory, and subsequent changes in facts and circumstances will not result in the restoration or increase in that newly established cost basis. If inventory with a lower cost basis is subsequently sold, it will result in higher gross margin for those sales. In 2021, the Company recognized no charges arising from excess inventory.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Intangible Assets</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">On July 1, 2019, the Company entered into a confirmatory assignment of patents and trademarks agreement that included all intangible product rights for the SANCUSO Product for $31.5 million.  The value of the intangible product rights is being amortized on a straight-line basis over the remaining lives of such intangible product rights, which end on December 31, 2024.  The Company evaluates its long-lived assets including definite lived and indefinite lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Recoverability of these assets is measured by comparison of their carrying amounts to future undiscounted cash flows that the assets are expected to generate.  If long-lived assets are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair market value and is recorded in the period the determination was made.  Based upon management&#8217;s assessment, there was no impairment of long-lived assets at September 30, 2021.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">At September 30, 2021, the Company&#8217;s intangible assets future amortization expense will be $1.4 million for the three months ended December 31, 2021, and $5.7 million each year for 2022, 2023, and 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:126pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SANCUSO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> PRODUCT LINE OF KYOWA KIRIN, INC.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOTES TO SPECIAL PURPOSE FINANCIAL STATEMENTS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">(continued)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies &#8211; continued </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Revenue Recognition</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company recognizes revenue when control of the promised goods is transferred to the customer in an amount that reflects the consideration the Company expects to receive in exchange for those goods.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Product Sales</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company recognizes revenue upon shipment to the customer as that is when the customer obtains control of the promised goods.  The Company typically extends credit terms to customers based on their creditworthiness and generally do not receive advance payments.  As such, the Company records accounts receivable at the time of shipment, when the right to the consideration becomes unconditional.  Accounts receivable from customers are typically due within 30 &#8211; 60 days of invoicing.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Performance Obligations</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Product sales do not include multiple performance obligations.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Judgments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company considers several factors in determining that control transfers to the customer upon delivery of goods.  These factors include that legal title transfers to the customer, the Company has a present right to payment, and the customer has assumed the risks and rewards of ownership at the time of shipment.  During the nine months ended September 30, 2021, product returns were not significant.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Shipping and Handling Costs</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Costs for shipping and handling activities are recorded as cost of sales and are expensed as incurred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research and Development Expenses</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development expenses are recorded in the period that services are rendered or goods are received. Research and development expenses consist of fees paid to related third parties that conduct certain research and development activities on our behalf. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">C.  Prepaid Expenses</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prepaid expenses consisted of the following at September 30, 2021&#58;</font></div><div><font><br></font></div><div style="padding-left:65.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.275%"><tr><td style="width:1.0%"></td><td style="width:72.070%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prescription drug user fee amendments (PDUFA)</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.1pt;padding-right:6.7pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$      369,413</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font><br></font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:126pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SANCUSO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> PRODUCT LINE OF KYOWA KIRIN, INC.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOTES TO SPECIAL PURPOSE FINANCIAL STATEMENTS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">(continued)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">D.&#160;&#160;&#160;&#160;Inventories</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Inventories consisted of the following at September 30, 2021&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:65.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.275%"><tr><td style="width:1.0%"></td><td style="width:72.070%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Raw materials</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.1pt;padding-right:6.7pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$                 -</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Finished goods</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.1pt;padding-right:6.7pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,223,776</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:3.1pt;padding-right:6.7pt;text-align:right"><font><br></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:3.1pt;padding-right:6.7pt;text-align:right"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:3.1pt;padding-right:6.7pt;text-align:right"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.1pt;padding-right:6.7pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$   1,223,776</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:3.1pt;padding-right:6.7pt;text-align:right"><font><br></font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>5
<FILENAME>exhibit993unauditedproform.htm
<DESCRIPTION>EX-99.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icf6154008ad042478343e09ceeae6e51_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Unaudited Pro Forma Condensed Combined Financial Statements (referred to as the &#8220;pro forma financial statements&#8221;) presented below are derived from the historical consolidated financial statements of Cumberland Pharmaceuticals, Inc. (&#8220;Cumberland&#8221; or the &#8220;Company&#8221;) and the SANCUSO Product Line of Kyowa Kirin, Inc. (&#8220;Kyowa Kirin&#8221;).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">On December 31, 2021, Cumberland signed and entered into a definitive agreement (the &#8220;Agreement&#8221;) to acquire the U.S. rights to SANCUSO&#174; (the &#8220;SANCUSO Product&#8221;) from Kyowa Kirin (the &#8220;Acquisition&#8221;). Under the terms of the Agreement, Cumberland acquired the U.S. rights to the SANCUSO Product and assumed full commercial responsibility for the product &#8211; including its marketing, promotion, distribution, manufacturing and medical support activities. The SANCUSO Product is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Unaudited Pro Forma Condensed Combined Statements of Operations presented below (the &#8220;pro forma statements of operations&#8221;) for the year ended December&#160;31, 2020 and the nine months ended September 30, 2021, give effect to the Acquisition as if it was consummated on January&#160;1, 2020. The Unaudited Pro Forma Condensed Combined Balance Sheet gives effect to the Acquisition as if it occurred on September 30, 2021. The unaudited pro forma financial statements are provided for informational purposes only and are not necessarily indicative of operating results that would have been achieved had the Acquisition been completed as of January 1, 2020 and do not intend to project the future financial results of Cumberland following the Acquisition.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The historical consolidated financial information has been adjusted in the pro forma financial statements to give effect to certain pro forma events that are&#58; (i)&#160;directly attributable to the Acquisition&#59; (ii) expected to have a continuing impact on the Company&#8217;s combined results&#59; and (iii)&#160;factually supportable. The basis and estimates underlying the pro forma adjustments are described in the accompanying notes, which should be read in connection with the pro forma financial statements.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 805,&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">Business Combinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;(&#8220;ASC 805&#8221;) as updated by Accounting Standards Update 2017-01 (&#34;ASU 2017-01), the Acquisition is being accounted for as a business combination with Cumberland acquiring the SANCUSO Product assets. As of the date of this report, we have not completed the valuation necessary to arrive at the final estimates of fair value of the SANCUSO Product&#8217;s assets acquired, the contingent consideration and the related purchase price allocation. However, Cumberland believes that the Acquisition meets the definition of a business under the accounting guidance in ASC 805, as amended. Additionally, for purposes of these pro forma financial statements, preliminary allocation estimates based on information known to management as of the date of this report have been included. The final fair value of the assets acquired, the contingent consideration and the liabilities assumed as of the date of the Acquisition may differ materially from the information presented herein.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The pro forma financial statements reflect the following transactions, which took place in 2021&#58; (i) the Acquisition&#59; and (ii)&#160;the use of $13.5 million of cash to make the initial payment for the Acquisition.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">We describe the assumptions, which management believes are reasonable, underlying the pro forma adjustments in the accompanying notes. These assumptions should also be read in conjunction with these </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">unaudited pro forma financial statements. It is important to note that these assumptions do not reflect the future significant cost savings, benefits or synergies from the Acquisition.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">You should also read this information in conjunction with&#58;</font></div><div><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.204%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Audited consolidated financial statements of Cumberland as of and for the fiscal year ended <br>December 31, 2020, included in Cumberland&#8217;s Annual Report on Form 10-K for the fiscal </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">year ended December 31, 2020, filed with the SEC on March 12, 2021&#59;</font></div><div><font><br></font></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Audited special purpose financial statements of the SANCUSO Product line of Kyowa Kirin as </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">of and for the fiscal year ended December 31, 2020, together with the notes thereto and the </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">independent auditors&#8217; report thereon, included as Exhibit 99.1 to this Form 8-K&#47;A&#59;</font></div><div><font><br></font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.060%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Unaudited consolidated financial statements of Cumberland as of and for the nine months </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">ended September 30, 2021, included in Cumberland's Quarterly Report on Form 10-Q for the </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">nine months ended September 30, 2021, filed with the SEC on November 12, 2021&#59;</font></div><div><font><br></font></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Unaudited special purpose financial statements of the SANCUSO Product line of Kyowa Kirin as </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">of September 30, 2021 and for the nine months ended September 30, 2021, included as </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Exhibit 99.2 to this Form 8-K&#47;A&#59; and</font></div><div><font><br></font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.060%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Unaudited Pro Forma Condensed Combined Financial Statements (Combined Cumberland and </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">SANCUSO Product line of Kyowa Kirin) and the accompanying notes.</font></div><div><font><br></font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div><font><br></font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Unaudited Pro Forma Condensed Combined Balance Sheet</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">As of September 30, 2021</font></div><div style="margin-bottom:7pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.639%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.639%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.193%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.639%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Cumberland Historical</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Sancuso Historical</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Pro Forma Adjustments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Pro Forma Combined</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">ASSETS</font></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Current assets&#58;</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="5" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">25,843,231</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(13,500,000</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(a)</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="11" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">12,343,231</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accounts receivable, net</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9,850,530</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9,850,530</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Inventories, net</font></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10,262,769</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,223,776</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">11,486,545</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other current assets</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,259,098</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">369,413</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,628,511</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total current assets</font></td><td colspan="6" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">47,215,628</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,593,189</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(13,500,000</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="12" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">35,308,817</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Non-current inventories</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9,476,737</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9,476,737</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Property and equipment, net</font></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">493,488</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">493,488</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Intangible assets, net</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">24,918,830</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">18,619,115</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(769,337</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(b)</font></td><td colspan="12" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">42,768,608</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Goodwill</font></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">882,000</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">882,000</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating lease right-of-use</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,282,275</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,282,275</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other assets</font></td><td colspan="6" style="background-color:#ccecff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,301,816</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="6" style="background-color:#ccecff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="6" style="background-color:#ccecff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="12" style="background-color:#ccecff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,301,816</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total assets</font></td><td style="border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="5" style="border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">87,570,774</font></td><td colspan="3" style="border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="5" style="border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">20,212,304</font></td><td colspan="3" style="border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="3" style="border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(14,269,337</font></td><td colspan="3" style="border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="11" style="border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">93,513,741</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:2pt double #000000;padding:0 1pt"></td><td colspan="9" style="border-top:2pt double #000000;padding:0 1pt"></td><td colspan="9" style="border-top:2pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt double #000000;padding:0 1pt"></td><td colspan="12" style="border-top:2pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">LIABILITIES AND EQUITY</font></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Current liabilities&#58;</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accounts payable</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="5" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9,233,383</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9,233,383</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating lease current liabilities</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,094,187</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,094,187</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other current liabilities</font></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7,617,913</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,200,000</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(c)</font></td><td colspan="12" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8,817,913</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total current liabilities</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">17,945,483</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,200,000</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">19,145,483</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Revolving line of credit</font></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">15,000,000</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">15,000,000</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating lease non-current liabilities</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">229,605</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">229,605</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other long-term liabilities</font></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7,749,421</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4,742,967</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="12" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">12,492,388</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total liabilities</font></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">40,924,509</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,942,967</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">46,867,476</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Commitments and contingencies</font></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Equity&#58;</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Shareholders&#8217; equity&#58;</font></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Common stock-no par value</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">48,612,935</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">48,612,935</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Retained earnings</font></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,790,903</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">20,212,304</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(20,212,304</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(d)</font></td><td colspan="12" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,790,903</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total shareholders&#8217; equity</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">46,822,032</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">20,212,304</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(20,212,304</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">46,822,032</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Noncontrolling interests</font></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(175,767</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="12" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(175,767</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total equity</font></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">46,646,265</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">20,212,304</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(20,212,304</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">46,646,265</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total liabilities and equity</font></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="5" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">87,570,774</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="5" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">20,212,304</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(14,269,337</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="6" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">93,513,741</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">See accompanying Notes to Pro Forma Condensed Combined Financial Statements.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Unaudited Pro Forma Condensed Combined Statements of Income</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">For the Nine Months Ended September 30, 2021</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:7pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.889%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.573%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.889%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.573%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.889%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.573%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Cumberland Historical</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Sancuso Historical</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Pro Forma Adjustments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Pro Forma Combined</font></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Revenues&#58;</font></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net product revenue</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="5" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">26,855,753</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="5" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9,619,070</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="12" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">36,474,823</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other revenue</font></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">809,429</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">809,429</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net revenues</font></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">27,665,182</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9,619,070</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">37,284,252</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Costs and expenses&#58;</font></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cost of products sold</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,486,005</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,455,129</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1.37pt 0 1pt"></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6,941,134</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Selling and marketing</font></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">11,709,445</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,907,522</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1.37pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">13,616,967</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4,071,638</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1.37pt 0 1pt"></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4,071,638</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">General and administrative</font></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6,367,438</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">252,324</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1.37pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6,619,762</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Amortization</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,354,080</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4,296,719</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,619,252)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(e)</font></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6,031,547</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total costs and expenses</font></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">30,988,606</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7,911,694</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,619,252</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">37,281,048</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating income (loss)</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(3,323,424</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,707,376</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,619,252</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,204</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest income</font></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">19,411</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1.37pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">19,411</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other income</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,187,140</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1.37pt 0 1pt"></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,187,140</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest expense</font></td><td colspan="6" style="background-color:#ccecff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(70,297</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1.37pt 0 1pt"></td><td colspan="3" style="background-color:#ccecff;border-bottom:1pt solid #000000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="12" style="background-color:#ccecff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(70,297</font></td><td colspan="3" style="background-color:#ccecff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:24.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations before income taxes</font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:24.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Taxes</font></div></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,187,170</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,707,376</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,619,252</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,139,458</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Income tax (expense) benefit</font></td><td colspan="6" style="background-color:#ccecff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(22,375</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="6" style="background-color:#ccecff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1.37pt 0 1pt"></td><td colspan="3" style="background-color:#ccecff;border-bottom:1pt solid #000000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="9" style="background-color:#ccecff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(22,375</font></td><td colspan="6" style="background-color:#ccecff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net income (loss) from continuing operations</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,209,545</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,707,376</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,619,252</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,117,083</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Discontinued operations</font></td><td colspan="6" style="background-color:#ccecff;border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,491,004</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="6" style="background-color:#ccecff;border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="6" style="background-color:#ccecff;border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="15" style="background-color:#ccecff;border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,491,004</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net income (loss)</font></td><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">281,459</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,707,376</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,619,252</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,608,087</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net loss at subsidiary attributable to noncontrolling interests</font></td><td colspan="6" style="background-color:#ccecff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">58,651</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="6" style="background-color:#ccecff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1.37pt 0 1pt"></td><td colspan="3" style="background-color:#ccecff;border-bottom:1pt solid #000000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="9" style="background-color:#ccecff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">58,651</font></td><td colspan="6" style="background-color:#ccecff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net income (loss) attributable to common shareholders</font></td><td style="border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="5" style="border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">340,110</font></td><td colspan="3" style="border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="5" style="border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,707,376</font></td><td colspan="3" style="border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="5" style="border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,619,252</font></td><td colspan="3" style="border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="12" style="border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,666,738</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="9" style="background-color:#ccecff;border-top:2pt double #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#ccecff;border-top:2pt double #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#ccecff;border-top:2pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;border-top:2pt double #000000;padding:0 1pt"></td><td colspan="15" style="background-color:#ccecff;border-top:2pt double #000000;padding:0 1pt"></td><td colspan="6" style="border-top:2pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Earnings (loss) per share attributable to common shareholders&#58;</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Basic</font></td><td style="background-color:#ccecff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="5" style="background-color:#ccecff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">0.02</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="9" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="9" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="6" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="9" style="background-color:#ccecff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">0.25</font></td><td colspan="6" style="background-color:#ccecff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Diluted</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="5" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">0.02</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">0.24</font></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Weighted-average common shares outstanding&#58;</font></td><td colspan="9" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="9" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="9" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="15" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Basic</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">14,939,919</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">14,939,919</font></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Diluted</font></td><td colspan="6" style="background-color:#ccecff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">15,139,904</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="9" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="9" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="15" style="background-color:#ccecff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">15,139,904</font></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">See accompanying Notes to Pro Forma Condensed Combined Financial Statements.</font></div><div style="margin-top:6pt"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Unaudited Pro Forma Condensed Combined Statements of Income</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">For the Year Ended December 31, 2020</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:7pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.806%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.933%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.933%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.248%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.349%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.649%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.248%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Cumberland Historical</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Sancuso Historical</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Pro Forma Adjustments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Pro Forma Combined</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Revenues&#58;</font></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net product revenue</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="5" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">35,840,673</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="5" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">16,171,293</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="5" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">52,011,966</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other revenue</font></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,600,461</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1.37pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,600,461</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net revenues</font></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">37,441,134</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">16,171,293</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,612,427</font></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,427</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Costs and expenses&#58;</font></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cost of products sold</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8,653,020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,160,987</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10,814,007</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Selling and marketing</font></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">14,765,465</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4,636,827</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">19,402,292</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,773,825</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,126,548</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6,900,373</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">General and administrative</font></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10,196,299</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">328,176</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10,524,475</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Amortization</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4,434,120</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,728,958</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2,159,002</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(e)</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8,004,076</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total costs and expenses</font></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">43,822,729</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">13,981,496</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2,159,002</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">55,645,223</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating income (loss)</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(6,381,595</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,189,797</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,159,002</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2,032,796</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest income</font></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">75,345</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">75,345</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest expense</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(263,627</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(263,627</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Income (loss) before income taxes</font></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(6,569,877</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,189,797</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,159,002</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2,221,078)</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Income tax (expense) benefit</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(55,902</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(55,902</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net income (loss)</font></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(6,625,779</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,189,797</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,159,002</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2,276,980)</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Discontinued operations, net of tax</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,206,875</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,206,875</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net income (loss)</font></td><td colspan="6" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(3,418,904</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="6" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,189,797</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,159,002</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">929,895</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net loss at subsidiary attributable to noncontrolling interests</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">79,496</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1.37pt 0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">79,496</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net income (loss) attributable to common shareholders</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(3,339,408</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="5" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,189,797</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="5" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,159,002</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="5" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,009,391</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:2pt double #000000;padding:0 1pt"></td><td colspan="9" style="border-top:2pt double #000000;padding:0 1pt"></td><td colspan="9" style="border-top:2pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt double #000000;padding:0 1pt"></td><td colspan="9" style="border-top:2pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Earnings (loss) per share attributable to common shareholders&#58;</font></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Basic</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.22</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="5" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">0.07</font></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.22</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">)</font></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="5" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">0.07</font></td><td colspan="6" style="background-color:#ccecff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Weighted-average common shares outstanding&#58;</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Basic</font></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">15,162,184</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">15,162,184</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Diluted</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">15,162,184</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">15,359,794</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">See accompanying Notes to Pro Forma Condensed Combined Financial Statements.</font></div><div style="margin-bottom:17pt;margin-top:17pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Notes to Unaudited Pro Forma Condensed Combined Financial Statements</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The pro forma adjustments described below are based on our preliminary estimates and assumptions that are subject to change. The final purchase price allocation may vary based on final valuations and analyses of the fair value of the acquired assets and assumed liabilities. Cumberland is in the process of working with its advisors to complete the purchase price allocation for the value of intangible assets, useful life of the intangible assets, the fair value of the earnout, and the fair value of the future royalty payments. Accordingly, the pro forma adjustments are preliminary and have been made solely for illustrative purposes.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The following adjustments have been reflected in the unaudited pro forma condensed combined financial information&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">Adjustments to the Unaudited Pro Forma Condensed Combined Balance Sheet</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(a) Preliminary purchase price consideration&#58;</font></div><div><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.314%"><tr><td style="width:1.0%"></td><td style="width:73.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.702%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="18" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Cash payment upon closing</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">13,500,000</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Expected cash payment during 2023-2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1,500,000</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Fair value of royalty payments</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">4,442,967</font></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Total fair value of consideration transferred</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="6" style="border-bottom:2.5pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">$</font></td><td colspan="3" style="border-bottom:2.5pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">19,442,967</font></td><td colspan="3" style="border-bottom:2.5pt double #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The Company paid $13,500,000 at closing. The estimated $1,500,000 liability reflects the following&#58; $1,000,000 payment upon the successful technology approval and FDA approval of the transition of the Kindeva manufacturing site from Minnesota to their facility in Northridge California which is expected in 2023&#59; a $500,000 payment for the transfer of the NDA to the Company, which is expected in 2024&#59; and a onetime payment of $2,000,000 upon the attainment of $20,000,000 of annual net sales. Based on our current projections, the Company does not expect the $20,000,000 of annual sales milestone to be reached.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The fair value of royalty payments reflects the estimated fair value of the future net sales royalty payments under the agreement. As part of the Acquisition, Cumberland will pay tiered royalties up to 10% on future U.S. net sales of the SANCUSO Product. Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and as a result the future royalty payments are required to be recognized at the acquisition-date fair value as part of the acquisition consideration.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(b) Reflects the preliminary fair value of $17,849,778 for identifiable intangible assets. The identifiable intangible assets include U.S. Food and Drug Administration Orange Book listed patents. The intangible assets are being amortized using the straight-line amortization method over their currently estimated useful life of five years.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(c) Reflects the current and noncurrent components of the fair value of the milestone and future royalty payment liabilities of $5,942,967 described in Note (a). The Company estimated the current portion of the milestone and future royalty payments to be $1,200,000 and the estimated noncurrent portion to be $4,742,967.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(d) Reflects the elimination of the SANCUSO Product historical equity accounts.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">Adjustments to the Unaudited Pro Forma Condensed Combined Statements of Operations</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(e) Reflects the decrease in amortization expense from the preliminary valuation of the SANCUSO Product intangible assets acquired described in Note (b). The intangible assets are being amortized over their currently estimated useful life of ten years.</font></div><div><font><br></font></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:1px"></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">These pro forma financial statement adjustments do not reflect any reductions for transaction costs that resulted from the Acquisition nor do they consider any in-process research and development assets. Cumberland did not identify any transaction costs or in-process research and development costs that would require capitalization or inclusion in these pro forma adjustments.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:125%">Cost savings related to synergies</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The combined pro forma financial information does not reflect the realization of any expected cost savings or other synergies from the acquisition of SANCUSO Product. We expect that there will be future significant cost savings in the selling, marketing, general and administrative expenses through the synergies of Cumberland promoting the product with its existing and expected planned infrastructure. Cumberland also expects to experience significant future improvements in the costs of research and development, compared to historical experience.  Although the Company believes such cost savings and other synergies will be realized following the asset acquisition, there can be no assurance that these cost savings or any other synergies will be fully achieved.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:125%">Preliminary purchase price allocation and assumptions</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">As noted previously, the pro forma adjustments are based on our preliminary estimates and assumptions that are subject to change. The final fair value of the contingent consideration and the final purchase price allocation may vary based on final valuations and analyses of the fair value of the acquired assets and assumed liabilities. Cumberland is in the process of working with its advisors to complete the purchase price allocation and is further evaluating the step-up in value of intangible assets, the useful life of the intangible assets, the fair value of the earnout, and the fair value of the future royalty payments. Cumberland agreed to pay tiered royalties up to 10% on future U.S. net sales of the SANCUSO Product. As part of the purchase price allocation Cumberland must recognize the estimated fair value of these tiered royalties as contingent consideration. Under ASC 805, the resulting liability is required to be remeasured at fair value through net income (loss) at the end of each reporting period.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cpix-20220317.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e2c3d170-12b7-41fc-8d34-d657306939bd,g:ac02975c-0cd6-434a-8ef5-7392c7d87dc7-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://cumberlandpharma.com/20220317" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cumberlandpharma.com/20220317">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20220317_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20220317_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20220317_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument">
        <link:definition>0001001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>cpix-20220317_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e2c3d170-12b7-41fc-8d34-d657306939bd,g:ac02975c-0cd6-434a-8ef5-7392c7d87dc7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="cpix-20220317.xsd#DocumentandEntityInformationDocument"/>
  <link:definitionLink xlink:role="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument" xlink:type="extended" id="ia092942ab8c64f91a2c2bc79d731e178_DocumentandEntityInformationDocument">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_57d497bc-2035-4590-a53f-08c944c2e09e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_DocumentType_57d497bc-2035-4590-a53f-08c944c2e09e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_729b413e-ae48-4a0f-ac3c-8c4d963ee9c0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_DocumentPeriodEndDate_729b413e-ae48-4a0f-ac3c-8c4d963ee9c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9d6766f0-f533-4823-8558-06389528abce" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_EntityRegistrantName_9d6766f0-f533-4823-8558-06389528abce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3cf62ffd-2e54-4c83-b048-cfdd254de260" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_EntityCentralIndexKey_3cf62ffd-2e54-4c83-b048-cfdd254de260" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8398f9b7-af3d-497e-93af-bd2707e924ab" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_AmendmentFlag_8398f9b7-af3d-497e-93af-bd2707e924ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f48e82d7-1438-46ce-b643-ecbcf9484425" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f48e82d7-1438-46ce-b643-ecbcf9484425" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1923ac9c-5d11-4388-a2f4-7fc5cb8ae4de" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_EntityFileNumber_1923ac9c-5d11-4388-a2f4-7fc5cb8ae4de" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_0d8d4ba3-c1db-4153-9c74-c0a3c56bbcc6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_EntityTaxIdentificationNumber_0d8d4ba3-c1db-4153-9c74-c0a3c56bbcc6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_bd52962f-4fb2-415f-b0db-ebbce39af607" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_CityAreaCode_bd52962f-4fb2-415f-b0db-ebbce39af607" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ab8a86c0-9de6-4e87-9ebd-3410ecb4547a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_LocalPhoneNumber_ab8a86c0-9de6-4e87-9ebd-3410ecb4547a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_6c46200b-03a3-4c6c-bd25-95d31ea1298a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_WrittenCommunications_6c46200b-03a3-4c6c-bd25-95d31ea1298a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_56aad937-ed8c-400a-8ac9-aa69c91e8bb3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_SolicitingMaterial_56aad937-ed8c-400a-8ac9-aa69c91e8bb3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_84d887ea-a147-413b-a154-7027bbfaa77b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_PreCommencementTenderOffer_84d887ea-a147-413b-a154-7027bbfaa77b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_e16d0893-5200-4f28-8c74-042e955f92be" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_e16d0893-5200-4f28-8c74-042e955f92be" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e73cec50-90f6-47e0-a5d0-caf4c405f893" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_Security12bTitle_e73cec50-90f6-47e0-a5d0-caf4c405f893" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e59cacac-9954-46c2-bce1-b0542e8d8b39" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_TradingSymbol_e59cacac-9954-46c2-bce1-b0542e8d8b39" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a46b46b4-cebe-4426-901b-3006ec7eb840" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_SecurityExchangeName_a46b46b4-cebe-4426-901b-3006ec7eb840" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c1d4f156-abbb-455a-93d9-9c6bd141c57c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_EntityEmergingGrowthCompany_c1d4f156-abbb-455a-93d9-9c6bd141c57c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f9ebead6-14d9-4f24-96c7-648c98c4ac64" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_EntityAddressAddressLine1_f9ebead6-14d9-4f24-96c7-648c98c4ac64" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_077b5627-7793-4ffd-945c-b259c5a12e1a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_EntityAddressPostalZipCode_077b5627-7793-4ffd-945c-b259c5a12e1a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_90dbc462-4a04-4e3e-a91b-481f2258c45c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_EntityAddressCityOrTown_90dbc462-4a04-4e3e-a91b-481f2258c45c" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b6930afa-89bb-4afc-bac4-35746d3f2079" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_EntityAddressStateOrProvince_b6930afa-89bb-4afc-bac4-35746d3f2079" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_1bad7318-dc8e-4080-a280-87a7b9dbe19a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_EntitiesTable_1bad7318-dc8e-4080-a280-87a7b9dbe19a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>cpix-20220317_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e2c3d170-12b7-41fc-8d34-d657306939bd,g:ac02975c-0cd6-434a-8ef5-7392c7d87dc7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_01660ed2-2c84-4c3b-9b42-9884e944e653_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c7003719-3ec1-4827-bb14-1e1959eaa7fc_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9bf79a64-7345-4841-b6bc-93d3c547c123_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a2300435-3b47-48da-bd17-2f3afd33275d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a7635095-453d-41d5-86e9-5646733a6c59_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_45365976-3845-4910-a58e-443aca24a579_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_07157555-e940-4d46-abde-f66d67c11ab4_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_d52d979d-1788-4c8b-b3c7-7fe9ffe1319d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_33632e27-5a2a-49d2-9a52-7b82a183d957_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8d621ecb-b327-45e4-b9c8-c6f711b6797e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f31f9d2f-57bc-49d2-b7a8-3d2ce4f8c8d8_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_aeac6e71-1b6a-4c18-b826-e3a376765661_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_afee2b15-fe82-4ebf-bf25-4365f14b0022_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f174102f-4e25-47fe-b032-4557d50d29b4_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f4ab698b-e4f0-487d-b6ea-7c1582da6201_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_eacd54eb-b3cb-4058-8903-71b29c02a8e2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_2c5ec5cb-2989-4921-9d63-ee079ca356bb_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_231b19c8-88d3-4b14-a687-534e332e3e0b_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_51dc455e-40d4-480c-9673-0123395a0310_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8beee420-3b6a-4904-8910-bba9b183eb6e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_77814a7b-b668-49ee-a347-82ff7ea30a89_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c8a66173-d3a9-4e6c-9022-b56ed9106cee_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_58e39406-f9fd-4a68-8e25-b59d8e635039_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_be0e629e-7bf8-4762-832c-963261c38d8b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_766d727e-5f6d-4699-9ef1-455d22767107_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>cpix-20220317_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e2c3d170-12b7-41fc-8d34-d657306939bd,g:ac02975c-0cd6-434a-8ef5-7392c7d87dc7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="cpix-20220317.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_783d6a55-6fcb-40c2-8aeb-452482258149" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_1bad7318-dc8e-4080-a280-87a7b9dbe19a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_783d6a55-6fcb-40c2-8aeb-452482258149" xlink:to="loc_dei_EntitiesTable_1bad7318-dc8e-4080-a280-87a7b9dbe19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_1bad7318-dc8e-4080-a280-87a7b9dbe19a" xlink:to="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_57d497bc-2035-4590-a53f-08c944c2e09e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_DocumentType_57d497bc-2035-4590-a53f-08c944c2e09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_729b413e-ae48-4a0f-ac3c-8c4d963ee9c0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_DocumentPeriodEndDate_729b413e-ae48-4a0f-ac3c-8c4d963ee9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9d6766f0-f533-4823-8558-06389528abce" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_EntityRegistrantName_9d6766f0-f533-4823-8558-06389528abce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3cf62ffd-2e54-4c83-b048-cfdd254de260" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_EntityCentralIndexKey_3cf62ffd-2e54-4c83-b048-cfdd254de260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8398f9b7-af3d-497e-93af-bd2707e924ab" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_AmendmentFlag_8398f9b7-af3d-497e-93af-bd2707e924ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f48e82d7-1438-46ce-b643-ecbcf9484425" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f48e82d7-1438-46ce-b643-ecbcf9484425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1923ac9c-5d11-4388-a2f4-7fc5cb8ae4de" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_EntityFileNumber_1923ac9c-5d11-4388-a2f4-7fc5cb8ae4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_0d8d4ba3-c1db-4153-9c74-c0a3c56bbcc6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_EntityTaxIdentificationNumber_0d8d4ba3-c1db-4153-9c74-c0a3c56bbcc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_bd52962f-4fb2-415f-b0db-ebbce39af607" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_CityAreaCode_bd52962f-4fb2-415f-b0db-ebbce39af607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ab8a86c0-9de6-4e87-9ebd-3410ecb4547a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_LocalPhoneNumber_ab8a86c0-9de6-4e87-9ebd-3410ecb4547a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_6c46200b-03a3-4c6c-bd25-95d31ea1298a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_WrittenCommunications_6c46200b-03a3-4c6c-bd25-95d31ea1298a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_56aad937-ed8c-400a-8ac9-aa69c91e8bb3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_SolicitingMaterial_56aad937-ed8c-400a-8ac9-aa69c91e8bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_84d887ea-a147-413b-a154-7027bbfaa77b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_PreCommencementTenderOffer_84d887ea-a147-413b-a154-7027bbfaa77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_e16d0893-5200-4f28-8c74-042e955f92be" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_e16d0893-5200-4f28-8c74-042e955f92be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e73cec50-90f6-47e0-a5d0-caf4c405f893" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_Security12bTitle_e73cec50-90f6-47e0-a5d0-caf4c405f893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e59cacac-9954-46c2-bce1-b0542e8d8b39" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_TradingSymbol_e59cacac-9954-46c2-bce1-b0542e8d8b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a46b46b4-cebe-4426-901b-3006ec7eb840" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_SecurityExchangeName_a46b46b4-cebe-4426-901b-3006ec7eb840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c1d4f156-abbb-455a-93d9-9c6bd141c57c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_EntityEmergingGrowthCompany_c1d4f156-abbb-455a-93d9-9c6bd141c57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f9ebead6-14d9-4f24-96c7-648c98c4ac64" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_EntityAddressAddressLine1_f9ebead6-14d9-4f24-96c7-648c98c4ac64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_077b5627-7793-4ffd-945c-b259c5a12e1a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_EntityAddressPostalZipCode_077b5627-7793-4ffd-945c-b259c5a12e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_90dbc462-4a04-4e3e-a91b-481f2258c45c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_EntityAddressCityOrTown_90dbc462-4a04-4e3e-a91b-481f2258c45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b6930afa-89bb-4afc-bac4-35746d3f2079" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3a6ba887-5e69-4cb9-9876-4c327920a543" xlink:to="loc_dei_EntityAddressStateOrProvince_b6930afa-89bb-4afc-bac4-35746d3f2079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@  #+(    +" (   !>-])%    @$E$051X7NW!
M 0$   @"(/^?UA\%)
M
M                       \5             X9H#+R%E=/]?H     245.
%1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140645476165688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>Mar. 17, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 17,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CUMBERLAND PHARMACEUTICALS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1765329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-0068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPIX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2525 West End Avenue, Suite 950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>cpix-20220317_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cpix-20220317.xsd" xlink:type="simple"/>
    <context id="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2022-03-17</startDate>
            <endDate>2022-03-17</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xMC9mcmFnOjA1ODA0NWI0MmIyYzQxNjQ4MTQ1NzQxMTliMDhiN2JhL3RhYmxlOjFkYjU4NTFkMzk3NzRkMDRiZWJiYjQyZmY2MzFkZmYzL3RhYmxlcmFuZ2U6MWRiNTg1MWQzOTc3NGQwNGJlYmJiNDJmZjYzMWRmZjNfMi0xLTEtMS0xMjg0Mg_97956d8a-1a0c-42ad-851f-5a2a7d989fae">0001087294</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xMC9mcmFnOjA1ODA0NWI0MmIyYzQxNjQ4MTQ1NzQxMTliMDhiN2JhL3RhYmxlOjFkYjU4NTFkMzk3NzRkMDRiZWJiYjQyZmY2MzFkZmYzL3RhYmxlcmFuZ2U6MWRiNTg1MWQzOTc3NGQwNGJlYmJiNDJmZjYzMWRmZjNfMy0xLTEtMS0xMjg0Mg_8b9ddb8f-16e6-4fb9-8f27-2f5c900d4812">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNzA3_b37a371f-20d5-4db2-9aea-3d85ba8ad6ea">8-K/A</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNzY_a869308b-6b60-4a72-948e-e633f3b1d50d">2022-03-17</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNzAy_9e5b82d6-eb94-4f5b-ab08-7f1dbf7c25cf">CUMBERLAND PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGFibGU6MDU4NjMzMzdiMzJkNDhmMzkyNzc0NDM5YmIxZTRmNmMvdGFibGVyYW5nZTowNTg2MzMzN2IzMmQ0OGYzOTI3NzQ0MzliYjFlNGY2Y18wLTAtMS0xLTEyODQy_1a0d9c83-e2dc-466d-9fe3-5063dac300d7">TN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGFibGU6MDU4NjMzMzdiMzJkNDhmMzkyNzc0NDM5YmIxZTRmNmMvdGFibGVyYW5nZTowNTg2MzMzN2IzMmQ0OGYzOTI3NzQ0MzliYjFlNGY2Y18wLTEtMS0xLTEyODQy_879b4da5-86f7-44c5-af61-809db6193c1b">001-33637</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGFibGU6MDU4NjMzMzdiMzJkNDhmMzkyNzc0NDM5YmIxZTRmNmMvdGFibGVyYW5nZTowNTg2MzMzN2IzMmQ0OGYzOTI3NzQ0MzliYjFlNGY2Y18wLTMtMS0xLTEyODQy_8e624602-5b23-43e4-b643-c5d15008287c">62-1765329</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNzAz_65b23342-238a-4665-ad0e-dfcbb2631db4">2525 West End Avenue, Suite 950</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNzA0_3a831763-e4c4-4c5d-9bb4-fe0eeae6c66a">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNjk3_803c9990-8157-424b-93b4-cd5ed80a8f4e">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNjk4_4bdc2e6a-0366-496c-92bd-d14945ea21a2">37203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNjk5_d3d533d8-a9eb-43a5-a2c5-d550d90e8e7d">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNzA4_632761c7-a9d8-47a7-b48a-b47b83966be3">255-0068</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNzAw_37c409fd-1794-4538-9937-bea49e185d98">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNzA5_a5ab4699-45eb-43fc-b0de-1dbfe62be8c4">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNzAx_53bdb7de-3713-4642-afe3-b098d436b0c9">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNzA1_d2e54366-e415-410a-8036-5f65eb86b793">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGFibGU6NDU2MGFlYWRjMDVhNGFmOGExNWFhNTg0MTE4NmRiNDAvdGFibGVyYW5nZTo0NTYwYWVhZGMwNWE0YWY4YTE1YWE1ODQxMTg2ZGI0MF8xLTAtMS0xLTEyODQy_4c5644a3-db5b-487b-8752-5df79bf6cf14">Common Stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGFibGU6NDU2MGFlYWRjMDVhNGFmOGExNWFhNTg0MTE4NmRiNDAvdGFibGVyYW5nZTo0NTYwYWVhZGMwNWE0YWY4YTE1YWE1ODQxMTg2ZGI0MF8xLTEtMS0xLTEyODQy_a192c411-38e6-46f9-b591-e9ca06dabb9c">CPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGFibGU6NDU2MGFlYWRjMDVhNGFmOGExNWFhNTg0MTE4NmRiNDAvdGFibGVyYW5nZTo0NTYwYWVhZGMwNWE0YWY4YTE1YWE1ODQxMTg2ZGI0MF8xLTItMS0xLTEyODQy_60d397c0-d771-47ed-918f-b3ed0563c1ff">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNzA2_0069f2a8-b71f-4334-adb9-afd7554dc29f">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityEmergingGrowthCompany
      contextRef="i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317"
      id="id3VybDovL2RvY3MudjEvZG9jOjBhNTVhYWVmOGY3NTRlMGQ5MTk3NmM2MDcwY2IxOGZmL3NlYzowYTU1YWFlZjhmNzU0ZTBkOTE5NzZjNjA3MGNiMThmZl8xL2ZyYWc6ZDYzZGQwZTMzNTliNDExM2I2NTFhNzU2NjIwNTcxMWYvdGV4dHJlZ2lvbjpkNjNkZDBlMzM1OWI0MTEzYjY1MWE3NTY2MjA1NzExZl8xNjk1_0069f2a8-b71f-4334-adb9-afd7554dc29f">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MS1D8L?L WB^5LH<;=T8M_L4P_!=02P,$%     @ H(AQ5)^@&_"Q @  X@P
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M$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ H(AQ5 =!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" "@B'%4FV_#H^X    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " "@B'%4F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( *"(<53K
MGGE 3 0  &X0   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " "@B'%4GZ ;\+$"  #B#   #0
M    @ &/#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( *"(<527BKL<P
M !,"   +              "  6L/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M *"(<50<.&7J/P$  #P"   /              "  500  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " "@B'%4)!Z;HJT   #X 0  &@
M@ ' $0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "@
MB'%499!YDAD!  #/ P  $P              @ &E$@  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     "0 ) #X"  #O$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>118</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cpix-20220317.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K/A" original="cpix-20220317.htm">cpix-20220317.htm</File>
    <File>cpix-20220317.xsd</File>
    <File>cpix-20220317_def.xml</File>
    <File>cpix-20220317_lab.xml</File>
    <File>cpix-20220317_pre.xml</File>
    <File>exhibit231consentofindepen.htm</File>
    <File>exhibit991auditedspecialpu.htm</File>
    <File>exhibit992unauditedspec.htm</File>
    <File>exhibit993unauditedproform.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cpix-20220317.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "cpix-20220317_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cpix-20220317.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20220317_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20220317_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cpix-20220317.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 118,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "cpix",
   "nsuri": "http://cumberlandpharma.com/20220317",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220317.htm",
      "contextRef": "i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information Document",
     "role": "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument",
     "shortName": "Document and Entity Information Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220317.htm",
      "contextRef": "i0d327b01e42b4500910479aa7f2a3de2_D20220317-20220317",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001628280-22-006570-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-006570-xbrl.zip
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ME+=GE,QYCSE_^,@4F>=J_\4)+Y*H.M2[0EF'(MP#F-9+ A8J<>,!<FD8WZ#
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MA&S4('<,A>7&<H(*A07&(;3N\EES%0,\>0E&<02L>9-C_W^17SMIE%&=9V^
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M7!.:NH2/D$\>WO[Q\6P;:5%ULUBL9@]C9JXL$?%ZAN[N"HZG;;&Z*F%S;=E
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M!^83BH@ $8"P+L^H3B+YL;2]YW1GTVU3:%(H[%O>Y?FRKC9!Q&&@,%F@Q$9
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MBO)"2#.SZ&MOY<.->76V2.<W,[-^[[HP2;O;65$TO%8H>842T@KEW[L&FPR
M_T1XRUVL3P"N#O?]4V'<Q^G[)X-[:><'<WS &\,,AKP\H=YF>JQS]W&HP="/
MC_BI3HN\%+,13HL?PVQ GE5O7-A7JV$J1WLFTWJ<U=2] =7<ER;39CE;-EP'
MJ7YU9E]-M4FG'PMSGL]MWE.F2GZ7U3'%AR0QQ32$E(9&(X!43 !16 (N"0(\
MCHGAA!@:X6GY>&9/30;^_+P&48_D,LR91Y1EAUH+L\AO"_4CS\UG;<G+YJTJ
MT\633,S-XD:L#K!8JY)@"?^U10K4!M1@B36HP;Z<_ BN-Z^SD=B:G2)1N6H
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MT ;@M%J'NC(3W(#Y5=/,!Z/,V'7T%M_SE>B!$$=;1HP[V*-P#$@2%@4.[G3
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MSQ;1 DF456-[/5P?6S?&UHVQ=6-LW1A;-\:&NS%<[;H;HS^5$D>_W;DNDL+
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M;[],M\U&;;_167FWK5JCT5ZHUV=4[FK7&LU7*[:S,)7G>;@I&W:J,=H+(]]
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M#^8FAUO)="S("_.'8D3DY&,@"9( K9LZNQZB<826!PM42L-93#PV4#R26B1
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M;4R@I#0HG<Q1DVIV6HKN6IL#:U.T2Y_[7 ]9'W1G(3+LZIN4*)G9IN8A0?A
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M$<39[<7!%/XS3$;AV_\"4$L#!!0    ( *"(<52= $L;DRP  .?7 @ >
M97AH:6)I=#DY,W5N875D:71E9'!R;V9O<FTN:'1M[3UK<]LXDM_O5^ R<[.>
M*ECA4Q3M;*H\3K+KVQEG-G9J:C]=021D84*16C[L:'_]-4!2HIXF)4KB:ZLV
M8YLD@&[TNQN-=__]X?/MX[]^_XC&X<1!OW_]Y=>[6_3F\NW;/]3;MV\_/'Y
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MW[:3:)4SPV*#%Z:"P$[PFL3BMC^L?0*/8 <68&:P#@(X-G.RZNN;Z[VX?,>
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MW#;?EG7095EK?;;Y<C;L5 T'VHCI?09:/_QYEB6U+$?_Z]W-+W>_WCW>?7Q
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MQ@'^MJKR[O-Y>O2='F&5HZLU=_QTJ)$VJ=7*(6@[X^DGIB.!+JG:[%=F4.-
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M"1U]\CQ;;.0'/WI"-S8L@L4Y64#L9Y_GY-$OGO<--$0@<I>P+>Y\HK6Q14$
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M0\^>P7_&X<1Y__]02P$"% ,4    " "@B'%4]"ZZ-XT<  ",O   $0
M        @ $     8W!I>"TR,#(R,#,Q-RYH=&U02P$"% ,4    " "@B'%4
MNI_&"90"  #9"   $0              @ &\'   8W!I>"TR,#(R,#,Q-RYX
M<V102P$"% ,4    " "@B'%4:C'18','   ",P  %0              @ %_
M'P  8W!I>"TR,#(R,#,Q-U]D968N>&UL4$L! A0#%     @ H(AQ5":_@XXI
M"P  P64  !4              ( !)2<  &-P:7@M,C R,C S,3=?;&%B+GAM
M;%!+ 0(4 Q0    ( *"(<50CX>%@)P<  ' V   5              "  8$R
M  !C<&EX+3(P,C(P,S$W7W!R92YX;6Q02P$"% ,4    " "@B'%42CZ9(.X"
M  !7"   '@              @ ';.0  97AH:6)I=#(S,6-O;G-E;G1O9FEN
M9&5P96XN:'1M4$L! A0#%     @ H(AQ5 3)?5L['0  \]T  !X
M     ( !!3T  &5X:&EB:70Y.3%A=61I=&5D<W!E8VEA;'!U+FAT;5!+ 0(4
M Q0    ( *"(<52K-*]-UQ@  &NZ   ;              "  7Q:  !E>&AI
M8FET.3DR=6YA=61I=&5D<W!E8RYH=&U02P$"% ,4    " "@B'%4G0!+&Y,L
M  #GUP( '@              @ &,<P  97AH:6)I=#DY,W5N875D:71E9'!R
?;V9O<FTN:'1M4$L%!@     )  D = (  %N@      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
